Various outcomes of cholinesterase inhibitor treatment influence survival of patients with Alzheimer’s disease.

Forskningsoutput: KonferensbidragPoster


Objectives: Various outcomes of cholinesterase inhibitor (ChEI) therapy have been observed in Alzheimer’s disease (AD). It is not clear whether the duration of treatment, type of ChEI, or dose affect mortality. We aimed to investigate the association between ChEI therapy and patient survival. Methods: The Swedish Alzheimer Treatment Study (SATS) is a prospective, observational, multicentre study to evaluate long-term treatment with ChEIs in clinical practice. This study included 1021 outpatients with a clinical diagnosis of mild-to-moderate AD (Mini-Mental State Examination score, 10–26) at the start of ChEI treatment (shortly after diagnosis). The date of death of participants was recorded. Results: After up to 16 years of follow-up, 841 (82%) of the patients in the SATS had died. The mean ± standard deviation time from diagnosis of AD to death was 6.0 ± 2.9 years, and differed between individuals with varying durations of ChEI treatment in the study, from 7.2 ± 2.5 years (3-year completers) to 4.9 ± 2.9 years (<1 year) (P<0.001). Patients who received a higher mean dose of ChEIs during the study had a longer lifespan than those who received a lower dose (6.4 ± 2.9 vs 5.5 ± 2.8 years; P<0.001). The median cutoff values were donepezil 6.9 mg, rivastigmine 6.0 mg, and galantamine 15.0 mg. No difference in mortality between the types of ChEIs was found after adjusting for sex, age, and disease severity. Conclusions: Longer survival can be expected for AD patients who receive and tolerate higher ChEI doses and a longer duration of treatment.


Enheter & grupper

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Neurologi
StatusPublished - 2015
Peer review utfördNej
Evenemang12th International Conference on Alzheimer`s and Parkinson`s Diseases (AD/PD 2015) - Nice, Frankrike
Varaktighet: 2015 mar 182015 mar 22


Konferens12th International Conference on Alzheimer`s and Parkinson`s Diseases (AD/PD 2015)


Ingen tillgänglig data